A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs CLR 457 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 26 Apr 2019 Planned number of patients changed from 163 to 157.
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2018 The overall toxicity profile of patient in dose escalation phase lead the study Investigators and Sponsor to terminate the study, according to results published in the Investigational New Drugs.